S. Suciu

Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.

A. Eggermont, C. Punt, P. Patel, 2006, European journal of cancer.

Modulation of multidrug-resistant multiple myeloma by cyclosporin

P. Sonneveld, R. Zittoun, S. Suciu, 1992, The Lancet.

High tPA-expression in primary melanoma of the limb correlates with good prognosis

A. Eggermont, U. Kleeberg, H. Straatman, 2000, British Journal of Cancer.

Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952.

A. Eggermont, V. Cocquyt, P. Patel, 2011, European journal of cancer.

Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781).

P. Steerenberg, S. Suciu, E. Macher, 1993, European journal of cancer.

Ulceration of primary melanoma and responsiveness to adjuvant interferon therapy: Analysis of the adjuvant trials EORTC18952 and EORTC18991 in 2,644 patients.

A. Eggermont, A. Testori, P. Patel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.